Mcdonald Partners LLC Sells 1,602 Shares of Amgen Inc. $AMGN

Mcdonald Partners LLC lowered its position in shares of Amgen Inc. (NASDAQ:AMGN) by 9.1% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 16,069 shares of the medical research company’s stock after selling 1,602 shares during the quarter. Amgen accounts for approximately 1.7% of Mcdonald Partners LLC’s investment portfolio, making the stock its 14th biggest holding. Mcdonald Partners LLC’s holdings in Amgen were worth $5,260,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of AMGN. Board of the Pension Protection Fund bought a new position in shares of Amgen during the 4th quarter worth approximately $26,000. Olistico Wealth LLC bought a new position in shares of Amgen during the 4th quarter worth approximately $33,000. Cloud Capital Management LLC bought a new position in shares of Amgen during the 3rd quarter worth approximately $34,000. Ares Financial Consulting LLC bought a new position in shares of Amgen during the 4th quarter worth approximately $34,000. Finally, Saranac Partners Ltd bought a new position in shares of Amgen during the 3rd quarter worth approximately $37,000. Institutional investors own 76.50% of the company’s stock.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q1 results beat expectations — AMGN reported $5.15 EPS vs. $4.73 consensus and product sales rose ~4%, with 16 drugs delivering double‑digit growth, supporting the company’s growth story. Amgen’s Q1 Earnings Top Estimates
• Positive Sentiment: Bullish analyst action — Goldman Sachs reiterated a Buy and lifted its price target to $425, signaling long‑term upside from execution and pipeline momentum. Goldman Sachs Raises PT to $425
• Positive Sentiment: Other supportive analyst notes — Some firms (e.g., William Blair) reiterated Buy ratings after the quarter, highlighting confidence in the MariTide/weight‑loss program and execution. Analyst Reiterates Buy
• Neutral Sentiment: Guidance set but roughly in line — Amgen updated FY‑2026 EPS guidance to $21.70–$23.10 (consensus ~22.29), which many read as broadly in‑line rather than materially bullish. Amgen FY2026 Guidance (press release/slide)
• Neutral Sentiment: Small, mixed analyst target moves — Truist nudged its target to $327 with a Hold rating (minimal change), leaving some investors watching for clearer directional signals. Truist Raises PT to $327
• Negative Sentiment: FDA action risk — The FDA proposed withdrawing Tavneos approval after alleging clinical‑trial data issues, raising regulatory, compliance and reputational concerns that can pressure the stock. FDA Tavneos Proposal Coverage
• Negative Sentiment: Investor apprehension over strategy/timing — Some market commentary framed the quarter as “generally in‑line” and expressed concern about Amgen’s aggressive push into obesity (MariTide) and the near‑term profit impact, contributing to selling pressure. Investor Reaction to MariTide Expansion

Wall Street Analyst Weigh In

AMGN has been the subject of several research analyst reports. Jefferies Financial Group initiated coverage on shares of Amgen in a research note on Tuesday, March 10th. They set a “hold” rating and a $350.00 price target for the company. Morgan Stanley set a $332.00 price target on shares of Amgen in a research note on Friday. Piper Sandler raised their price target on shares of Amgen from $381.00 to $432.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. Wall Street Zen lowered shares of Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Finally, Truist Financial raised their price target on shares of Amgen from $325.00 to $327.00 and gave the stock a “hold” rating in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $357.54.

Amgen Stock Down 4.7%

AMGN opened at $329.82 on Friday. The company has a 50 day moving average of $358.07 and a 200 day moving average of $340.79. The company has a market cap of $178.00 billion, a PE ratio of 22.95, a price-to-earnings-growth ratio of 3.26 and a beta of 0.44. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $391.29. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $4.77 by $0.38. The company had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 139.90%. Amgen’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period last year, the firm earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, sell-side analysts expect that Amgen Inc. will post 22.28 EPS for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a $2.52 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 3.1%. Amgen’s dividend payout ratio (DPR) is 70.84%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.